Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ

35.52

+1.49(+4.38%)

Updated at June 02 10:35AM

Currency In USD

Valuation

Market Cap3.81B
Enterprise Value3.68B
P/E Ratio-6.02
PEG Ratio-0.83
Price/Sales Ratio5.5
Price/Book Ratio22.93
Enterprise/Revenue5.35
Enterprise/EBITDA-7.02

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterMarch 31, 2025

Profitability

Profit Margin-0.93
Operating Margin-0.87

Management Effectiveness

Return On Assets-0.42
Return On Equity-1.86

Income Statement

Revenue560.23M
Revenue/Share6.13
Gross Profit483.5M
EBITDA-469M
Net Income-569.18M
Diluted EPS-6.29

Balance Sheet

Total Cash494.44M
Total Cash/Share5.13
Total Debt38.27M
Total Debt/Equity0.27
Current Ratio2.4
Book Value Per Share1.57

Price History

52-Week Change-16.5
52-Week High60.37
52-Week Low29.59
Moving Average 50 Days36.01
Moving Average 200 Days45.37

Statistics

Average Volume933,450
Shares Outstanding94.54M
% Held by Institutions92.25

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A